Preferred Label : Belantamab Mafodotin;

NCIt synonyms : J6M0-mcMMAF; Belantamab Mafodotin-blmf;

NCIt definition : An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), conjugated to mafodotin, an auristatin analogue and microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration of belantamab mafodotin, the anti-BCMA antibody moiety selectively binds to BCMA on tumor cell surfaces. Upon internalization, the MMAF moiety binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces tumor cell apoptosis. In addition, belantamab mafodotin induces antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of cellular proliferation in tumor cells that overexpress BCMA. BCMA, a receptor for a proliferation-inducing ligand and B-cell activating factor, is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. Afucosylation of the antibody moiety increases ADCC.;

UNII : DB1041CXDG;

CAS number : 2050232-20-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2050232-20-5 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Blenrep;

Molecule name : GSK2857916;

NCI Metathesaurus CUI : CL471808;

Codes from synonyms : 4380;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3224946/fr/blenrep
2020
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
infusions, intravenous
Belantamab Mafodotin
antibodies, monoclonal, humanized
adult
antineoplastic agents
Belantamab Mafodotin
antibodies, monoclonal, humanized
multiple myeloma
belantamab mafodotin
belantamab mafodotin
belantamab mafodotin

---
https://www.ema.europa.eu/en/medicines/human/EPAR/blenrep
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Belantamab Mafodotin
Belantamab Mafodotin
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
antineoplastic agents
antineoplastic agents
multiple myeloma
adult
orphan drug production
infusions, intravenous
continuity of patient care
drug monitoring
belantamab mafodotin
product surveillance, postmarketing
aged
pregnancy
breast feeding
fertility
drug evaluation, preclinical
belantamab mafodotin
belantamab mafodotin
b-cell maturation antigen

---
Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.